Clinical Prior Authorization Update for VMAT2 Inhibitors Scheduled for August 13, 2020
VDP routinely updates existing clinical prior authorization criteria to reflect recent FDA-approved indications or safety information from the product package insert. FirstCare will revise the Austedo (deutetrabenazine) criteria within the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors clinical prior authorization on August 13, 2020:
* Required field
ATTENTION: By clicking “Continue”, you will be leaving the FirstCare Medicare Dual SNP (HMO SNP) site pages. If you wish to remain on these pages, simply click “Cancel” or close this box.